(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 28.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Alnylam Pharmaceuticals's revenue in 2025 is $2,248,243,000.On average, 11 Wall Street analysts forecast ALNY's revenue for 2025 to be $371,435,623,938, with the lowest ALNY revenue forecast at $361,514,286,416, and the highest ALNY revenue forecast at $386,727,362,119. On average, 11 Wall Street analysts forecast ALNY's revenue for 2026 to be $474,372,704,788, with the lowest ALNY revenue forecast at $411,146,865,455, and the highest ALNY revenue forecast at $818,104,497,342.
In 2027, ALNY is forecast to generate $624,285,256,551 in revenue, with the lowest revenue forecast at $483,033,129,610 and the highest revenue forecast at $1,217,699,900,767.